European Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 23 · Tue 17 Nov 

Companies

Compass Pathways

Compass Pathways plc

HQ
United Kingdom
Registry
Companies House · 12696098
Status
active
Listing
Listed · CMPS
Current stage
clinical-stage; rolling NDA with FDA, final submission "will be filed in the next two weeks" (Q3 release 2026-11-03); launch guided H1 2027 subject to FDA approval; cash $444.0m at 2026-09-30
Key people
Kabir Nath (CEO); Guy Goodwin (Chief Medical Officer)

sec.govregistryverified 2026-11-07

Notes on the record

Supersedes the row verified 2026-11-02 (kept), per DATA LAYER rule 4. Changed: current_stage, source_url. Q3 2026 10-Q 0001816590-26-000076 accepted 2026-11-03T13:07:22Z (sha256 prefix d7ea79b9317e) and 8-K 0001816590-26-000078 accepted 2026-11-03T13:22:18Z with EX-99.1 (sha256 prefix a988bce7128e); both read 2026-11-07. Issue 21 as sent (Beehiiv get_post_content, read 2026-11-07) says 'Compass has not filed Q3 results as of 2 November', true on its date; an earlier draft (the Issue 21 prose file on the bus) said 'Compass reports Q3 today, after this issue is sent', which the sent text does not contain. Both Compass filings were accepted before the 17:30Z send. The EX-99.1 has 0 hits for Europe, European, EMA, MHRA. The 10-Q states the company has not completed an NDA or an MAA to EMA or MHRA, and discloses no EMA or MHRA application. Cash $444.0m against $149.6m at 2025-12-31; debt $51.0m; net loss $9.8m for Q3 (a $40.8m warrant fair-value gain) and $172.4m for nine months. Companies House: collector found no change 2026-11-03 to 2026-11-07. Supersedes the C004-compass row verified 2026-11-07 (kept): no fact changed; the notes drop an internal file path that the site's leak check refuses on a rendered page (10 Nov 2026).

Assets

  • COMP360

    Phase 3 complete (COMP005, COMP006); rolling NDA, final submission "will be filed in the next two weeks" (Q3 release, 2026-11-03) · treatment-resistant depression; PTSD programme separate

    sec.govregistryverified 2026-11-07

Registered trials

  • NCT05624268ClinicalTrials.gov

    PHASE3 · Treatment Resistant Depression · COMPLETED · United States

    clinicaltrials.govctgov registryverified 2026-08-31

  • NCT05711940ClinicalTrials.gov

    PHASE3 · Treatment Resistant Depression · ACTIVE_NOT_RECRUITING · Canada, Czechia, Denmark, France, Germany, Ireland, Netherlands, Poland, Spain, Sweden, United Kingdom, United States

    clinicaltrials.govctgov registryverified 2026-08-31

  • 2023-505268-12-00CTIS

    Therapeutic confirmatory (Phase III) · Treatment-resistant depression · Authorised · Czechia, Denmark, France, Germany, Ireland, Netherlands, Poland, Spain, Sweden

    euclinicaltrials.euctis registryverified 2026-08-31

  • NCT07570654ClinicalTrials.gov

    PHASE2;PHASE3 · PTSD - Post Traumatic Stress Disorder;PTSD;PTSD Symptoms;PTSD, Post Traumatic Stress Disorder · RECRUITING · Canada, United States

    clinicaltrials.govctgov registryverified 2026-11-07

Deals

This company is not a party to any row in data/deals.csv.

In the briefing

10 issues tagged COMPASS.

Record history